Tirzepatide Lowers Teen BMI 18.5 Percent In JAMA Trial
In a randomized trial of 160 adolescents at 31 centers in six countries, a weekly tirzepatide injection plus lifestyle counseling cut BMI by 18.5 percent over 72 weeks, and 53.5 percent of treated teens ended the trial below the obesity threshold.
Edited and fact-checked by Stephen Sprague
The trial was sponsored by Eli Lilly, and its authors say longer follow-up in a more diverse group of teenagers is needed before anyone knows how long the benefit lasts.
Aaron S. Kelly stood before an ObesityWeek audience in National Harbor, Maryland, on November 15 carrying 72 weeks of data on 160 teenagers. Kelly is a professor of pediatrics at the University of Minnesota Medical School, and he led SURMOUNT-ADOLESCENTS, a phase 3 trial testing once-weekly tirzepatide in adolescents with obesity. JAMA published the results the same day he presented them.
The teenagers were 12 to under 18 years old, with a mean age of 14.6 years and a mean starting BMI of 38.6, and girls made up 61.9 percent of the group. Thirty-one medical centers ran the trial across Canada, the Czech Republic, Israel, Italy, Poland and the United States, from October 16, 2023, to June 2, 2026. For every teen assigned a placebo injection, two received tirzepatide, with the dose rising every four weeks from 2.5 milligrams to a maximum tolerated dose of 5, 10 or 15 milligrams. Counseling on activity goals and balanced meals went to both groups.
By week 72, BMI in the tirzepatide group had fallen 18.5 percent on average while the placebo group's BMI had risen 0.5 percent, an estimated treatment difference of 19.0 percentage points. Among treated teens, 53.5 percent finished below the 95th percentile for BMI, the threshold the trial used for obesity, against 7.1 percent on placebo. Nearly half of the treated group cut BMI by at least 20 percent, body weight fell 16.9 percent on the primary analysis, and blood pressure, LDL cholesterol, triglycerides, blood sugar and insulin all improved as HDL cholesterol rose.
The drug mimics two gut hormones, GIP and GLP-1, and together they slow digestion and signal fullness to the brain. Lilly sells it as Zepbound for weight management and Mounjaro for diabetes, and regulators have approved it for adults with obesity. Kelly told the session the quality-of-life scores mattered as much as the scale did. Treated teens gained 8.5 points on the physical comfort section of the IWQoL-Kids questionnaire while the placebo group lost 1.8 points. 'If you ask a teenager what's most important to them, they want to keep up with their friends,' Kelly said. 'So we are really doing something in the here and now for these teenagers.'
Most side effects were digestive, and 81.5 percent of teens on tirzepatide reported gastrointestinal problems during treatment, mostly mild to moderate, compared with 54.9 percent on placebo. About 9.3 percent of the treated group stopped the drug early because of those effects. Height growth and puberty progression continued normally through the trial, two measures the team tracked closely because every participant was still developing.
The limits are printed in the paper itself, and they are substantial. The trial enrolled 160 teenagers, a small group for a drug a family might take for years, and only one participant had type 2 diabetes, so it says little about diabetes care. The group was not very diverse, many participants had already finished puberty, and no follow-up past 72 weeks shows whether the BMI reduction holds once the injections stop. Eli Lilly sponsored the trial and took part in its design, analysis and manuscript, and an editorial published alongside the study in JAMA urged caution about reading the results as a general answer for adolescent weight care.
A family asking a pediatrician about tirzepatide today will hear that the drug has no approval for adolescent obesity, and this trial is evidence an approval decision would weigh rather than the decision itself. Kelly's team also cautioned against pushing every teenager to the maximum tolerated dose, because adolescents are still developing and the lowest effective dose may do the work. The study the authors say has to come next is a longer one, run in a wider group of teenagers.
Sources
- Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial, JAMA, published online November 15, 2026 (DOI 10.1001/jama.2026.23420)
- SURMOUNT-ADOLESCENTS Trial: Tirzepatide Shows Cardiometabolic Benefits in Pediatric Obesity, Endocrinology Advisor, November 2026 (ObesityWeek presentation report)
- Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports, Medical Xpress, November 17, 2026
- Pediatric Obesity Pharmacotherapy: From Therapeutic Scarcity to Therapeutic Choice, JAMA editorial, published online November 15, 2026 (DOI 10.1001/jama.2026.22895)
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.